XML 32 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets
 6 Months Ended
Jun. 30, 2020
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Intangible Assets INTANGIBLE ASSETS
The following table summarizes our intangible assets, net (in millions):
 June 30, 2020December 31, 2019
 Gross 
Carrying
Amount		Accumulated
Amortization		Foreign Currency Translation AdjustmentNet Carrying AmountGross 
Carrying
Amount		Accumulated
Amortization		Foreign Currency Translation AdjustmentNet Carrying Amount
Finite-lived assets:
Intangible asset - sofosbuvir$10,720  $(4,603) $—  $6,117  $10,720  $(4,253) $—  $6,467  
Intangible asset - axicabtagene ciloleucel6,200  (933) —  5,267  6,200  (761) —  5,439  
Other1,098  (495) (4) 599  1,098  (454) (6) 638  
Total finite-lived assets18,018  (6,031) (4) 11,983  18,018  (5,468) (6) 12,544  
Indefinite-lived assets - IPR&D1,247  —  (5) 1,242  1,247  —  (5) 1,242  
Total intangible assets$19,265  $(6,031) $(9) $13,225  $19,265  $(5,468) $(11) $13,786  
Aggregate amortization expense related to finite-lived intangible assets was $282 million and $563 million for the three and six months ended June 30, 2020, respectively, $288 million and $587 million for the three and six months ended June 30, 2019, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Operations.
The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of June 30, 2020 (in millions):
Fiscal YearAmount
2020 (remaining six months)$562  
20211,125  
20221,125  
20231,125  
20241,125  
Thereafter6,921  
Total$11,983